← Back to Search

Other

LY3502970 (Dose Level 2) for Obesity

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 42 days
Awards & highlights

Study Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.

Eligible Conditions
  • Obesity
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 42 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 42 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary outcome measures
PK: Maximum Observed Concentration (Cmax) of LY3502970
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970
Pharmacodynamics (PD): Change From Baseline in Body Weight
+1 more

Side effects data

From 2022 Phase 2 trial • 383 Patients • NCT05048719
37%
Nausea
33%
Vomiting
26%
Diarrhoea
22%
Constipation
19%
Eructation
11%
Weight decreased
11%
Flatulence
11%
Dyspepsia
7%
Abdominal distension
7%
Haemoglobin decreased
7%
Decreased appetite
7%
Abdominal pain upper
7%
Retching
7%
Asthenia
7%
Urticaria
4%
Fatigue
4%
Arthralgia
4%
Hypertension
4%
Ischaemic stroke
4%
Lipase increased
4%
Palpitations
100%
80%
60%
40%
20%
0%
Study treatment Arm
36 mg LY3502970 - 1
12 mg LY3502970
24 mg LY3502970
36 mg LY3502970 - 2
45 mg LY3502970 - 1
Placebo
3 mg LY3502970
45 mg LY3502970 - 2
1.5 mg Dulaglutide

Trial Design

3Treatment groups
Experimental Treatment
Group I: LY3502970 (Dose Level 3)Experimental Treatment1 Intervention
LY3502970 administered orally.
Group II: LY3502970 (Dose Level 2)Experimental Treatment1 Intervention
LY3502970 administered orally.
Group III: LY3502970 (Dose Level 1)Experimental Treatment1 Intervention
LY3502970 administered orally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3502970
2021
Completed Phase 2
~1220

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,613 Previous Clinical Trials
3,200,857 Total Patients Enrolled
54 Trials studying Obesity
40,828 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
405,180 Total Patients Enrolled
37 Trials studying Obesity
20,547 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of LY3502970 in Healthy Overweight and Obese Participants
2022. "A Study of LY3502970 in Healthy Overweight and Obese Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05313802.
~25 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top